Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025. Related: Early access, Conference reports, Antiretrovirals, Drug resistance.
Early access
Potential for once-monthly oral PrEP using MK-8527
17 July 2025. Related: Early access, Conference reports, Treatment strategies.
Five doses a week could be a safe option for adults: crisis response to ART stock-outs
16 July 2025. Related: Early access, Conference reports, Treatment strategies.
5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no difference in clinical outcomes
16 July 2025. Related: Early access, Conference reports, Treatment strategies.
Signal that sliver of PEPFAR might be salvaged
16 July 2025. Related: Early access, Treatment access.
IAS 2025: “We will not be erased” – a community Call to Action
15 July 2025. Related: Early access, Conference reports, Treatment access, Activism & advocacy.
13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports
13 July 2025. Related: Early access, Conference reports, Activism & advocacy.
HIV cure research at IAS 2025
12 July 2025. Related: Early access, Conference reports.
Global Fund plans for lenacapavir PrEP in selected countries
9 July 2025. Related: Early access, Treatment access, HIV prevention and transmission.
Featured AIDS quilts at the Tate: reflection and also anger
8 July 2025. Related: In memory, Early access, Special reports.